News
Butter is not back. The science never left
A new study published in JAMA Internal Medicine (March 2025) examined dietary patterns and health outcomes in over 221,000 U.S. adults over 33 years.
March 30, 2025
News and Insights
News
Vaccines: A Key Weapon Against Antimicrobial Resistance (AMR)
🦠 Vaccines: A Key Weapon Against Antimicrobial Resistance (AMR) A recent WHO report underscores the powerful role of vaccines in the fight against AMR, estimating that better use of vaccines could reduce the global need for antibiotics by 2.5 billion defined daily doses annually—a 22% decrease. This could be a game-changer in reducing the misuse
October 14, 2024
Insights
The Current State of Resuming Clinical Trials in Ukraine
Despite the challenges posed by the ongoing conflict, Ukraine’s healthcare sector demonstrates remarkable resilience and adaptability. The country’s efforts to maintain and enhance its healthcare and research infrastructure are also keeping clinical trials on schedule. As we discussed in this article on Linkedin, over the past few decades, Ukraine has established itself as a strong option
July 15, 2024
News
43rd meeting of ISICEM
I enjoy working as CRO and Trial Acceleration company in the highly challenging setting of Intensive Care – as agile, committed smaller companies we can show we make a difference and large CRO fail on the need to be fast and flexible. I attended this 43rd meeting of ISICEM to keep up in sepsis, more
March 31, 2024
News
News for Gaea Trial Acceleration OÜ
Client 4SC AG: The Marketing Authorisation Application for resminostat has been accepted by the EMA as sufficient for examination. “Germany, 1 March 2024 – 4SC AG a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), announced today that that its MAA has been accepted by the EMA as sufficient
March 6, 2024